The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...

Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the promise of faster, less toxic treatment without lymphodepletion while raising ...

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...

Initial results as promising as those in lupus and other non-cancer diseases driven by B c ...

High manufacturing costs are limiting patient access to CAR T cell therapies, according to new research, which indicates that decentralization, vector-free modification technologies, and AI would help ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established ...

TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 ...

So far, the BCMA-targeted CAR has shown early success in four Australian multiple myeloma patients in a Phase I trial.

Every time our body encounters a new disease-causing agent, a crucial defense system called adaptive immunity comes into play ...